ダウンロード数: 154
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
jjco_hyy046.pdf | 270.37 kB | Adobe PDF | 見る/開く |
タイトル: | A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients |
著者: | Inoue, Satoshi Saito, Yoji Tsuneto, Satoru Aruga, Etsuko Ogata, Takeshi Uemori, Mitsutoshi |
著者名の別形: | 恒藤, 暁 |
キーワード: | hydromorphone morphine cancer pain opioid switching conversion ratio efficacy ratio |
発行日: | 1-May-2018 |
出版者: | Oxford University Press (OUP) |
誌名: | Japanese Journal of Clinical Oncology |
巻: | 48 |
号: | 5 |
開始ページ: | 442 |
終了ページ: | 449 |
抄録: | Objective: To confirm the morphine to hydromorphone conversion ratio for hydromorphone (DS-7113b) immediate-release tablets in cancer patients who achieved pain control with oral morphine. Methods: This was a multicenter, active-controlled, randomized, double-blind, parallel-group, comparative study (July 2013 to December 2014) at 39 Japanese sites. Seventy-one patients (aged >20 years) who had achieved pain control with morphine 60 mg/day and 90 mg/day were randomly allocated 1:1 to hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5 or 1:8, respectively, and treated for up to 5 days. The efficacy was evaluated as the pain control ratio. Results: The pain control ratio in the full analysis set was 83.3% (25/30) in the conversion ratio 1:5 group and 95.0% (38/40) in the conversion ratio 1:8 group, and both groups demonstrated highly successful pain control. The incidence of adverse events was 46.7% (14/30) in the conversion ratio 1:5 group and 58.5% (24/41) in the 1:8 group; the difference was not clinically relevant. Frequently observed adverse events (incidence ≥5%) were nausea, vomiting, diarrhea, somnolence and dyspnea. Conclusions: A high pain control ratio was maintained by a switch at either conversion ratio, and no notable difference was observed in the incidence of adverse events. A switch from morphine to hydromorphone is effective at a dose converted at ratios of 1:5 and 1:8. |
著作権等: | © The Author(s) 2018. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
URI: | http://hdl.handle.net/2433/233904 |
DOI(出版社版): | 10.1093/jjco/hyy046 |
PubMed ID: | 29635632 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。